FIELD: biotechnologies.
SUBSTANCE: invention relates to the extracted peptide which has an inducibility of cytotoxic T-lymphocytes (CTL), and also to its use. The offered peptide can be used in anticarcinogenic immunotherapy, namely, in anticarcinogenic vaccines.
EFFECT: invention allows to treat cancer in high efficient way.
20 cl, 8 dwg, 5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| UBE2T PEPTIDE AND VACCINES CONTAINING THE SAME | 2013 |
|
RU2663350C2 |
| TOPK PEPTIDES AND THEIR VACCINES | 2012 |
|
RU2633503C2 |
| PEPTIDE CANCER VACCINES EXPRESSING TUMOUR-SPECIFIC ANTIGENS | 2008 |
|
RU2464275C2 |
| FOXP3 PEPTIDE VACCINE | 2007 |
|
RU2473557C2 |
| EPITOPE WDRPUH PEPTIDES AND VACCINES, CONTAINING THEM | 2009 |
|
RU2514386C2 |
| PEPTIDE VACCINES FOR CANCER EXPRESSING MPHOSPH1 OR DEPDC1 POLYPEPTIDES | 2007 |
|
RU2469044C2 |
| NEIL3 PEPTIDES AND VACCINES INCLUDING SAME | 2010 |
|
RU2600888C2 |
| MYBL2 EPITOPE PEPTIDES AND VACCINES CONTAINING THEM | 2009 |
|
RU2496787C2 |
| MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THEM | 2012 |
|
RU2612905C2 |
| NEIL3 PEPTIDES AND VACCINES COMPRISING THEM | 2010 |
|
RU2733985C2 |
